Sollis Health Announces New Chief Operating Officer, Jia Jia Ye, as the Concierge Medical Provider Expands

Sollis Health, the first and only concierge urgent and emergency care provider, has named Jia Jia Ye as Chief Operating Officer, effective immediately. As the company’s COO, Ye will ensure that Sollis Health delivers unparalleled clinical quality and member experience, with the brand’s continued national expansion and growth.

“Jia Jia’s extensive experience in healthcare operations, particularly her achievements in scaling multi-site operations and enhancing customer experience, positions her exceptionally well to lead our team,” said Sollis Health CEO Brad Olson. “I am confident that with Jia Jia’s expertise, Sollis Health will continue delivering the highest quality of care and capability.”

Sollis staffs some of the industry’s leading clinicians and operators, and Ye will be responsible for managing operations for the team to successfully deliver on the company’s mission across its national network of centers, including those in New York City, Los Angeles, San Francisco and South Florida. Ye will be based at the Sollis headquarters in New York City, and she will report directly to CEO Brad Olson.

“I’m thrilled to join Sollis Health and help expand our reach, bringing top-tier clinical care and an exceptional member experience to more people,” said Ye. “I’m passionate about creating experiences that delight customers, and I’m committed to establishing Sollis as a trusted partner in health journeys across the nation.”

Ye has a proven track record of scaling tech-enabled healthcare companies that focus on elevating patient experience. At Oscar Health Insurance, Ye established industry-leading customer and provider support systems as VP of Service Experience, leading Oscar to become the highest-rated customer experience in the insurance industry. While at One Medical Group, she played a key role in national expansion as Director of Operations. Ye’s career began in healthcare investment banking and venture capital. Most recently, she co-founded and led Springtide Child Development as CEO, pioneering integrative and evidence-based autism care to transform patient outcomes in that underserved field.

Ye holds an MBA and MPH from UC Berkeley, and a BA in Economics from Harvard College. She also advises and invests in early-stage healthcare companies, and is consistently inspired by the extraordinary work and passion of her peers in the industry dedicated to improving the healthcare system.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.